These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24455220)

  • 41. Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level.
    Seña AC; Willis SJ; Hilton A; Anderson A; Wohl DA; Hurt CB; Muir AJ
    Public Health Rep; 2016; 131 Suppl 2(Suppl 2):57-64. PubMed ID: 27168663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa.
    Larson BA; Schnippel K; Ndibongo B; Xulu T; Brennan A; Long L; Fox MP; Rosen S
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):e13-7. PubMed ID: 22659650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers - Philadelphia, Pennsylvania, 2012-2014.
    Coyle C; Viner K; Hughes E; Kwakwa H; Zibbell JE; Vellozzi C; Holtzman D;
    MMWR Morb Mortal Wkly Rep; 2015 May; 64(17):459-63. PubMed ID: 25950252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrated Hepatitis C Testing and Linkage to Care at a Local Health Department Sexually Transmitted Disease Clinic: Determining Essential Resources and Evaluating Outcomes.
    Rhea S; Seña AC; Hilton A; Hurt CB; Wohl D; Fleischauer A
    Sex Transm Dis; 2018 Apr; 45(4):229-232. PubMed ID: 29465696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis C Virus Screening: A Review of the OraQuick Hepatitis C Virus Rapid Antibody Test.
    D'Angelo RG; Klepser M; Woodfield R; Patel H
    J Pharm Technol; 2015 Feb; 31(1):13-19. PubMed ID: 34860920
    [No Abstract]   [Full Text] [Related]  

  • 46. Barriers and facilitators of integrated hepatitis B, C, and HIV screening among pregnant mothers and their newborns attending maternal and newborn clinics in Koboko District, Uganda: A qualitative inquiry of providers' perspective.
    Alege JB; Oyore JP; Nanyonga RC; Musoke P; Orago ASS
    Res Sq; 2023 Dec; ():. PubMed ID: 38196577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis C Virus Screening of High-Risk Patients in a Canadian Emergency Department.
    Ragan K; Pandya A; Holotnak T; Koger K; Collins N; Swain MG
    Can J Gastroenterol Hepatol; 2020; 2020():5258289. PubMed ID: 32211349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lessons Learned From Global Hepatitis C Elimination Programs.
    Handanagic S; Shadaker S; Drobeniuc J; Tsereteli M; Alkhazashvili M; Adesigbin C; Adamu I; Adabe R; Agwuocha C; Adisa O; Azania A; Boeke CE; Ngwije A; Serumondo J; Armstrong PA
    J Infect Dis; 2024 May; 229(Supplement_3):S334-S341. PubMed ID: 37739781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
    Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
    J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Barriers to hepatitis C treatment among secondary needle and syringe program clients and opportunities to intervene.
    Gunn J; McNally S; Ryan J; Layton C; Bryant M; Walker S; O'Mahony C; Pedrana A
    Int J Drug Policy; 2021 Oct; 96():103387. PubMed ID: 34330571
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacist Comfort and Awareness of HIV and HCV Point-of-Care Testing in Community Settings.
    Min AC; Andres JL; Grover AB; Megherea O
    Health Promot Pract; 2020 Sep; 21(5):831-837. PubMed ID: 31257939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid hepatitis C testing among persons at increased risk for infection--Wisconsin, 2012-2013.
    Stockman LJ; Guilfoye SM; Benoit AL; Vergeront JM; Davis JP;
    MMWR Morb Mortal Wkly Rep; 2014 Apr; 63(14):309-11. PubMed ID: 24717818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison.
    Babigumira JB; Karichu JK; Clark S; Cheng MM; Garrison LP; Maniecki MB; Hamid SS
    BMJ Open; 2023 May; 13(5):e066770. PubMed ID: 37142306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.
    Treloar C; Rance J; Dore GJ; Grebely J;
    J Viral Hepat; 2014 Aug; 21(8):560-7. PubMed ID: 24299222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
    Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention.
    Alter MJ; Kuhnert WL; Finelli L;
    MMWR Recomm Rep; 2003 Feb; 52(RR-3):1-13, 15; quiz CE1-4. PubMed ID: 12585742
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.
    Smith BD; Morgan RL; Beckett GA; Falck-Ytter Y; Holtzman D; Teo CG; Jewett A; Baack B; Rein DB; Patel N; Alter M; Yartel A; Ward JW;
    MMWR Recomm Rep; 2012 Aug; 61(RR-4):1-32. PubMed ID: 22895429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does integrating viral hepatitis services into a public STD clinic attract injection drug users for care?
    Hennessy RR; Weisfuse IB; Schlanger K
    Public Health Rep; 2007; 122 Suppl 2(Suppl 2):31-5. PubMed ID: 17542450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.
    Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C
    Addiction; 2023 Jun; 118(6):1153-1160. PubMed ID: 36683132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis C virus infection in the 1945-1965 birth cohort (baby boomers) in a large urban ED.
    Allison WE; Chiang W; Rubin A; O'Donnell L; Saldivar MA; Maurantonio M; Dela Cruz J; Duvidovich S; Carmody E
    Am J Emerg Med; 2016 Apr; 34(4):697-701. PubMed ID: 26809931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.